World Radiopharmaceutical Therapy
Council (WRPTC) is an International Scientific Organization
with stake holders from all fields of nuclear medicine and
several allied clinical specialties, e.g., nuclear medicine
physicians, radiologists, internists, endocrinologists,
radiation oncologists, radio- chemists, physicists, medical
oncologists, rheumatologists, etc who share research commitments
to, and clinical practice in, therapeutic nuclear medicine.
The major objective of the WRPTC includes setting standards
for provision of radiopharmaceutical therapy, particularly
in the development of uniform protocols for clinical practice
of therapeutic nuclear medicine worldwide.
Radionuclides are being used extensively to provide palliative
and curative treatment in a number of malignant and benign
diseases. The potential of radionuclides for treating malignant
tumours has been recognized and put to use for the past
several decades. It has been possible to exploit the physiology
unique to an organ or a disease process to deliver the radionuclides
selectively to the sites of abnormality. Radioiodine treatment
of thyroid diseases (Thyroid cancer, Hyperthyroidism etc.),
I-131 MIBG therapy of neuro-endocrine tumours, radioimmunotherapy
of B-cell lymphoma, palliative treatment of metastatic bone
pain using bone seeking radiopharmaceuticals and radiosynovectomy
have all been established in therapeutic nuclear medicine.
The use of Rhenium 188 labeled compounds has shown great
potential in the treatment of a number of benign and malignant
disorders, including liver cancer (Re-188 Lipiodol), especially
in developing countries. Several potentially useful Lu-177
labeled are now undergoing clinical trials and will most
probably be available in near future for clinical use in
To-day radiopharmaceutical therapy is the fastest growing
branch of nuclear medicine. However, its practice in developing
countries is only beginning to gain ground after years of
trailing behind its use in the developed world. The establishment
and consolidation of radiopharmaceutical therapy has come
about as a result of a gradual change in the realization
of its importance, cost-effectiveness and practicality.
Availability of new generator produced, beta emitting radiopharmaceuticals
like Re-188 for use in hospital radiopharmacy facilities
has also enhanced the scope and practice of radionuclide
therapy in developing countries.
The current activities
of WRPTC include organization of
(1) biennial International Conferences on Radiopharmaceutical
(2) biennial International Symposium on Radiopharmaceutical
(3) Nuclear Medicine Updates and
(4) Radiopharmaceutical Therapy Colloquium
The Council had conducted several colloquia, two highly
successful conferences and one symposium in the past. The
ICRTs and ISRTs are biennial congresses held every alternate
year. We are extremely proud to have held two highly successful
and memorable conferences on Radiopharmaceutical Therapy,
the first in Cyprus in October 2005 (ICRT-2005) and the
second in Mongolia in September 2007 (ICRT-2007).
With regard to International Symposium on Radiopharmaceutical
Therapy (ISRT), the first International Symposium on Radiopharmaceutical
Therapy (ISRT-2008) was held recently in Goa, India in October
We are now announcing the next International Conference
on Radiopharmaceutical Therapy (ICRT-2008), which is scheduled
to be held in Cartagena, Colombia from 3-7 November 2009.
This conference is being organized in conjunction with the
22nd Congress of the Latin-American Association of Societies
of Nuclear Medicine and Biology (ALASBIMN).
The objectives of this Conference
are to evaluate the current status of radiopharmaceutical
therapy in the world in general and in the developing countries
in particular, to exchange information on the current advances
in the field between scientists from developed and developing
countries; to interact with user groups (clinicians, oncologists,
surgeons, radiopharmacists, chemists, scientists, medical
physicists, etc.) and to bring them the most important information
in the field, and to define future directions. The major emphasis
of the conference will be to involve the end-users and stake
holders of radionuclide therapy, e.g., oncologists, endocrinologists,
radiation oncologists, rheumatologists, hematologists, physicians
and surgeons. The objectives are to enhance awareness and
sell the technology to our clinical colleagues.
THE SCOPE AND TOPICS
TO BE COVERED
The Conference will cover topics
and issues on all aspects of radiopharmaceutical therapy through
a number of plenary lectures, papers, panel discussions and
interactive audiovisual sessions. The topics to be addressed
at the symposium include the following:
- Reviews in therapeutic radiopharmaceuticals
- Development of new radiopharmaceuticals
- Clinical overviews of the current
trends in radionuclide therapy
- Radionuclide therapy:
— Treatment of primary cancer,
— Treatment of metastatic disease,
— Pain palliation.
— Treatment of benign diseases (Rheumatoid arthritis,
- Prognostication in cancer therapy
- Molecular methods in radiopharmaceutical
- Treatment planning
- Use of new instruments (PET/CT,
dedicated cameras, hand held cameras, etc.) in radiopharmaceutical
- Therapy planning
- Drug resistance
- Radioimmuno-detection and therapy
- Infrastructure development
Through organization of this
conference we expect to accomplish the following
- To carry out an evaluation of the
current status of radiopharmaceutical therapy globally
- To help in the transfer of important
information on the current trends in radiopharmaceutical
therapy from developed to developing countries
- To involve our other non-nuclear
medicine clinical colleagues and other end-users of our
technology in a much more productive and positive manner
in decision making and implementing the radionuclide therapeutic
- To publish a technical document
based on the proceedings of the Symposium
- To promote radiopharmaceutical
therapy globally in general, and in developing countries
- To formulate a strategy for
promoting radiopharmaceutical therapy around the world.
The working language of the meeting
will be English. All communications, synopses, abstracts and
papers must be sent in English.
Participants who require a visa
to enter Colombia should submit the necessary application
to the nearest diplomatic or consular representative of Colombia
as soon as possible. A formal letter of invitation may be
provided (on request) by the local host in Colombia in case
a participant needs it for visa purpose.
The address of the
conference secretariat is:
Prof. A.K. Padhy MD, FAMS
Chairman, World Radiopharmaceutical Therapy Council
Department of Nuclear Medicine & PET
Singapore General Hospital
Block-2, Basement-1, Outram Road, Singapore-169608
Tel: +65-63214201; Fax: +65-62240938; Mob: +65-81287726
The Chairman of the Local
Organizing Committee in Colombia:
Dr. Patricia Bernal Trujillo MD
Department of Nuclear Medicine & PET
Fundacion Santa Fe de Bogota
Telephone: +57- 1- 6030303 -ext 5489; Mobile: +57- 3134224267.;
Fax: +57- 1- 2104214
CHANNELS OF COMMUNICATION
All professionals who intend to participate in the conference
should register on-line. All subsequent correspondence on
scientific and administrative matters should be sent to the
PAPERS AND POSTERS
All papers, apart from invited
review papers, must present original work; they should not
have been published elsewhere.
SUBMISSION OF EXTENDED
Persons who wish to present a
paper or poster at the conference must submit an extended
synopsis (in English) on line latest by Monday, 8 June 2009.
The synopsis should contain a maximum of 800 words and include
four clearly identifiable elements of content: Rationale,
methods, results and conclusion. The synopsis will be considered
by the Scientific Committee and if accepted - will be reproduced
in unedited form in a supplementary issue of the World Journal
of Nuclear Medicine.
In order to provide ample time
for discussion, the number of papers that can be accepted
for oral presentation is limited. If the number of relevant
and high quality papers submitted for selection exceeds the
acceptable number, some of them will be selected for presentation
as posters. Authors will be informed whether their papers/posters
have been accepted for presentation on the basis of the extended
synopsis. The WRPTC, however, reserves the right to refuse
the presentation or publication of any paper that does not
meet the expectations based on the information given in the
extended synopsis. Further details concerning the poster and
oral presentation at the meeting will be sent to all authors
in due course.
All professionals who intend to participate in the Symposium
should register on-line on or before 6 July 2009. Please note
that only on-line
registration is available. Registration is free for medical
and technical professionals as well as scientists and research
scholars working in the field of nuclear medicine and allied
specialties in hospitals, clinics, universities and other
non-commercial organizations which are engaged in the practice
of nuclear medicine.
Please note that free registration only applies to those participants
who opt for conference lump sum (please refer to the "EXPENDITURES"
A non-resident registration
fee will be charged to all those participants who would like
to attend the conference without opting for lump sum payment.
Details will be available on request from the local organisers.
Please note that this
conference is being held in conjunction with the 22nd meeting
of the ALASBIMN (5-7 November 2009). As a gesture of good-will
the organizers of ALASBIMN have promised to provide free registration
to all ICRT participants (from both ALASBIMN Member countries
as well as Non-ALASBIMN Member countries) to attend the ALASBIMN
scientific sessions. In this way all participants of ICRT
can enjoy the benefits from both ICRT-2009 as well as from
the ALASBIMN Congress. Similarly, all registered participants
of ALASBIMN will also have free registration for ICRT-2009.
statements mean the following:
- ICRT registration is free for
all those participants who opt for ICRT lump sum.
- Once you are registered for ICRT,
you will be automatically registered for ALASBIMN congress
also. This means you do not need to pay the ALASBIMN registration
- In this way, a participant would
save about $380.
Participants from Industry:
It may be noted that the organizers of both ICRT-2008 and
ALASBIMN have decided to have a common Commercial Exhibition,
starting from 4th to 7th November 2009. A certain number of
free registrations are provided to the representatives from
Industry and commercial organizations depending on their level
of sponsorship (Please see “Sponsorship” section
for more details). The sponsors may bring in additional participants
over and above their entitlement only after paying the additional
registration fee of the extra participants. The registration
fee for each additional participant from Industry and commercial
organizations is US$ 500.00. This registration fee entitles
the industry participant entry to both ICRT-2009 and ALASBIMN
venues (Scientific and Commercial).
from Industry without sponsorship:
Professionals from commercial organizations which do not intend
to sponsor the event(s), but would like their employees or
professionals attend the conference(s), are most welcome to
do so. The registration fee for such participants for the
entire duration from 3-7 November 2009 is US$ 500.00 per person.
This registration fee entitles the industry participants entry
to both ICRT-2009 and ALASBIMN venues (Scientific and Commercial).
But it does not allow them to indulge in any overt commercial
The conference will be held in
Cartagena, Colombia, which offers some of the magnificent
monuments, landscapes and tourist attractions in the world.
Dr. Patricia Bernal has been designated as the Chairman of
the Local Organizing Committee. We are inviting several International
organizations to collaborate with us in this Endeavour. We
are also expecting that the nuclear medicine industry would
participate in large numbers in the organization of the congress.
Please note that as a general rule the WRPTC does not pay
the cost of attendance, i.e. travel and living expenses, of
participants. In order to make it easy and possible for the
professionals from all over the world including from the developing
and least developed countries, the WRPTC in collaboration
with the local organizers, has developed a comprehensive package
which would include the following:
Accommodation in Hotel Hilton, Cartagena a first class hotel
in Cartagena for five nights and 6 days, all breakfasts, 4
lunches, 3 Dinners, 2 Parties, one full day Excursion w/Lunch
and airport transportation. The cost of this entire package
would be US$ 1500.00 in Single Accommodation and US$ 1840.00
in double accommodation. For two persons sharing a room the
cost of the entire package would be US$ 920.00 per person.
Please note that this is the best deal we could get after
a lot of negotiations with various hotels and agencies. Please
also note that there is no registration fee, registration
is free for ICRT-2009 for those who opt for the conference
lump sum. The registration for ALASBIMN Congress is also free
for all ICRT participants.
(Conditions apply: contact local organising committe for non-resident
registration fee for all those participants who do not wish
to opt for lump sum payment.)
Cartagena is one of the most spectacular tourist spots in
Latin America and November is the most important tourist month
in Cartagena. The tourist inflow to Cartagena is supposed
to be at its peak during this time of the year. We would therefore
request you to register and confirm your participation by
paying your lump-sum at the earliest. Please do not wait until
the deadline, since the rooms are limited and we reserve the
rooms on a first come first served basis.
We are planning to
organize the conference in a very friendly and cordial atmosphere,
offering positive interaction between professionals from all
fields of nuclear medicine. We will strive hard to accommodate
all participants in the best hotels in Cartagena (Hilton).
All academic, social and excursion activities will be organized
in such a way that everyone would get a chance to participate
in them. All in all every effort will be made to make it a
Detailed information on accommodation
and other items will be sent to all confirmed participants
well in advance of the meeting directly from Colombia.